Cargando…

Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer

BACKGROUND: S-1 and cyclophosphamide (CPA) can be given orally, and their combination may have great potential for treating metastatic breast cancer (MBC). A phase I study of sequential S-1 and CPA therapy was conducted in patients with MBC; the recommended doses that were determined for this regime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yanai, Keiko, Fujii, Takaaki, Horiguchi, Jun, Nakazawa, Yuko, Kurozumi, Sasagu, Obayashi, Sayaka, Yajima, Reina, Shirabe, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648287/ https://www.ncbi.nlm.nih.gov/pubmed/33158432 http://dx.doi.org/10.1186/s12885-020-07550-5

Ejemplares similares

Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer
por: Honda, Chikako, et al.
Publicado: (2021)

The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy
por: Nakazawa, Yuko, et al.
Publicado: (2020)

Oncological safety of immediate breast reconstruction with skin- or nipple-sparing mastectomy: the value of tumor-to-dermis distance measured by preoperative ultrasonography
por: Fujii, Takaaki, et al.
Publicado: (2021)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer
por: Handa, Tadashi, et al.
Publicado: (2019)

Thoracoscopic S(4)a subsegmentectomy combined with wedge resections for treatment of metastatic tumors located at the intersection of the major and minor fissures
por: Obayashi, Kai, et al.
Publicado: (2020)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2018)

Video-assisted thoracoscopic segmentectomy with combined chest wall resection: A case report
por: Ohtaki, Yoichi, et al.
Publicado: (2022)

RNA‐sequence‐based microRNA expression signature in breast cancer: tumor‐suppressive miR‐101‐5p regulates molecular pathogenesis
por: Toda, Hiroko, et al.
Publicado: (2019)

Clinical and anatomical features of the lateral costal artery and vein
por: Nakazawa, Seshiru, et al.
Publicado: (2022)

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2022)

Surgical outcomes after multiple segmentectomy: a cohort study
por: Nakazawa, Seshiru, et al.
Publicado: (2022)

Right upper lobe segmentectomy guided by simplified anatomic models
por: Nakazawa, Seshiru, et al.
Publicado: (2020)

Risk factors for late-onset pulmonary fistula after pulmonary segmentectomy
por: Kawatani, Natsuko, et al.
Publicado: (2023)

Clinicopathological features and surgical outcomes of lobectomy combined with segmentectomy: a cohort study
por: Nakazawa, Seshiru, et al.
Publicado: (2023)

Fibrocystic breast disease with pleomorphic calcifications and segmental distribution: A case report
por: JiueLan, Kuo, et al.
Publicado: (2023)

Quantitative analysis of metabolic parameters at (18)F-fluorodeoxyglucose positron emission tomography in predicting malignant potential of anterior mediastinal tumors
por: Yajima, Toshiki, et al.
Publicado: (2020)

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2011)

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
por: Yoshioka, T, et al.
Publicado: (2009)

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
por: Cottu, P H, et al.
Publicado: (2001)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

(18)F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation
por: Fujii, Takaaki, et al.
Publicado: (2017)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)
por: Riccardi, A, et al.
Publicado: (2001)

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2002)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
por: Kurozumi, Sasagu, et al.
Publicado: (2020)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Implication of atypical supraclavicular F18-fluorodeoxyglucose uptake in patients with breast cancer: Association between brown adipose tissue and breast cancer
por: Fujii, Takaaki, et al.
Publicado: (2017)

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial
por: Chen, Si-Yuan, et al.
Publicado: (2023)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
por: Green, J. A., et al.
Publicado: (1988)

A novel one-step lens cleaning device using air and water flow for endoscopic surgery
por: Tatsuki, Hironori, et al.
Publicado: (2018)

Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial
por: Spielmann, M, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_ste251q4ja3gb5mrfhnvm6n0sa